Trial Profile
This study investigated elbasvir/grazoprevir in patients with chronic Hepatitis C: A study from Trio health disease management program
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2018
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 19 Jul 2018 New trial record
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018